The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...
Two companies — Eli Lilly and Novo Nordisk — dominate the weight-loss drug market and their stocks have surged in the recent ...
While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback